Triapine and Gemcitabine Combination for Biliary Ducts and Gall Bladder Tumors

This is a phase 2 study focusing on treating cancers of the biliary ducts and gall bladder. It aims to evaluate the effectiveness of a combination treatment using two drugs: Triapine and Gemcitabine. The study is important as it seeks to find new ways to improve treatment for these types of cancers, potentially leading to better patient outcomes and addressing current challenges in their management. During the study, participants receive Triapine through an IV drip over 4 hours, followed by Gemcitabine through an IV infusion over 30 minutes. This treatment is given on days 1, 8, and 15 of each 28-day cycle. The cycle may repeat up to 12 times, depending on how the patient responds to the treatment and if they experience any unacceptable side effects. The study measures the results by assessing the tumor response every eight weeks using a CT scan and specific criteria (RECIST). It looks at how the tumor size changes, whether it decreases or disappears, to understand the effectiveness of the treatment.